High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. EORTC Genito-Urinary Tract Cancer Co-operative Group. EORTC Early Clinical Trials Group.
Eighteen patients with progressive disseminated, platinum-resistant germ cell tumors were treated with epirubicin 135 mg/m2, every 3 weeks. One patient had stable disease, 17 developed progression. Myelosuppression was dose-limiting. One patient died of neutropenic septicemia. High-dose epirubicin is not active against platinum-resistant germ cell cancer.
Stoter
G
G
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Akdas
A
A
Fosså
S D
SD
Kaye
S B
SB
van Groeningen
C J
CJ
Renard
J
J
van Glabbeke
M
M
D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D015251:Epirubicin / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*
D015251:Epirubicin